- Associated Press - Thursday, October 29, 2020

CAMBRIDGE, Mass. (AP) _ Blueprint Medicines Corp. (BPMC) on Thursday reported third-quarter net income of $634 million, after reporting a loss in the same period a year earlier.

The Cambridge, Massachusetts-based company said it had profit of $11.16 per share.

The results exceeded Wall Street expectations. The average estimate of eight analysts surveyed by Zacks Investment Research was for earnings of $6.49 per share.

The cancer drug developer posted revenue of $745.1 million in the period, also exceeding Street forecasts. Seven analysts surveyed by Zacks expected $565.9 million.

Blueprint Medicines shares have risen 31% since the beginning of the year. The stock has climbed 56% in the last 12 months.


This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on BPMC at https://www.zacks.com/ap/BPMC

Sign up for Daily Newsletters

Manage Newsletters

Copyright © 2020 The Washington Times, LLC.

Please read our comment policy before commenting.


Click to Read More and View Comments

Click to Hide